1
|
Sarkar OS, Donninger H, Al Rayyan N, Chew LC, Stamp B, Zhang X, Whitt A, Li C, Hall M, Mitchell RA, Zippelius A, Eaton J, Chesney JA, Yaddanapudi K. Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy. Sci Adv 2023; 9:eadg3736. [PMID: 37390211 PMCID: PMC10313166 DOI: 10.1126/sciadv.adg3736] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 05/26/2023] [Indexed: 07/02/2023]
Abstract
Immune checkpoint inhibitor (ICI) therapy is effective against many cancers for a subset of patients; a large percentage of patients remain unresponsive to this therapy. One contributing factor to ICI resistance is accumulation of monocytic myeloid-derived suppressor cells (M-MDSCs), a subset of innate immune cells with potent immunosuppressive activity against T lymphocytes. Here, using lung, melanoma, and breast cancer mouse models, we show that CD73-expressing M-MDSCs in the tumor microenvironment (TME) exhibit superior T cell suppressor function. Tumor-derived PGE2, a prostaglandin, directly induces CD73 expression in M-MDSCs via both Stat3 and CREB. The resulting CD73 overexpression induces elevated levels of adenosine, a nucleoside with T cell-suppressive activity, culminating in suppression of antitumor CD8+ T cell activity. Depletion of adenosine in the TME by the repurposed drug PEGylated adenosine deaminase (PEG-ADA) increases CD8+ T cell activity and enhances response to ICI therapy. Use of PEG-ADA can therefore be a therapeutic option to overcome resistance to ICIs in cancer patients.
Collapse
Affiliation(s)
- Omar S. Sarkar
- Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA
| | - Howard Donninger
- Department of Medicine, University of Louisville, Louisville, KY, USA
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA
- Experimental Therapeutics Program, University of Louisville, Louisville, KY, USA
| | - Numan Al Rayyan
- Department of Medicine, University of Louisville, Louisville, KY, USA
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA
- Natural Agricultural Research Center, P.O. Box 639, Baq'a 19381, Jordan
| | - Lewis C. Chew
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA
| | - Bryce Stamp
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA
| | - Xiang Zhang
- Department of Chemistry, University of Louisville, Louisville, KY, USA
| | - Aaron Whitt
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Chi Li
- Department of Medicine, University of Louisville, Louisville, KY, USA
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA
- Experimental Therapeutics Program, University of Louisville, Louisville, KY, USA
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
| | - Melissa Hall
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA
| | - Robert A. Mitchell
- Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA
- Department of Surgery, Division of Immunotherapy, University of Louisville, Louisville, KY, USA
- Immuno-Oncology Group, Brown Cancer Center, University of Louisville, Louisville, KY, USA
| | - Alfred Zippelius
- Center for Immunotherapy, Cancer Center Medical Oncology, University Hospital Basel, Switzerland
| | - John Eaton
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA
- Immuno-Oncology Group, Brown Cancer Center, University of Louisville, Louisville, KY, USA
| | - Jason A. Chesney
- Department of Medicine, University of Louisville, Louisville, KY, USA
- Department of Surgery, Division of Immunotherapy, University of Louisville, Louisville, KY, USA
- Immuno-Oncology Group, Brown Cancer Center, University of Louisville, Louisville, KY, USA
| | - Kavitha Yaddanapudi
- Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA
- Department of Surgery, Division of Immunotherapy, University of Louisville, Louisville, KY, USA
- Immuno-Oncology Group, Brown Cancer Center, University of Louisville, Louisville, KY, USA
| |
Collapse
|
2
|
Donninger H, Harrell-Stewart D, Clark GJ. Detection of Endogenous RASSF1A Interacting Proteins. Methods Mol Biol 2021; 2262:303-310. [PMID: 33977485 DOI: 10.1007/978-1-0716-1190-6_18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
RASSF1A is a Ras effector that promotes the anti-proliferative properties of Ras. It acts as a scaffold protein that regulates several pro-apoptotic signaling pathways, thereby linking Ras to their regulation. However, accumulating evidence suggests that RASSF1A functions as a regulator of other additional biological processes, such as DNA repair and transcription, thereby implicating Ras in the modulation of these biological processes. The mechanisms by which RASSF1A modulates these processes is not fully understood but likely involves interacting with other effectors associated with these functions and coordinating their activity. Thus, to fully understand how RASSF1A manifests its activity, it is critical to identify RASSF1A interacting partners.Unfortunately, the reagents available for the detection of RASSF1A are of poor quality and also exhibit low sensitivity. Here we describe an immunoprecipitation protocol, taking into consideration the limitations of currently available reagents, that can reliably detect the endogenous interaction between RASSF1A and its binding partners.
Collapse
Affiliation(s)
- Howard Donninger
- Department of Medicine, University of Louisville, Louisville, KY, USA
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA
| | | | - Geoffrey J Clark
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA.
| |
Collapse
|
3
|
Harrell Stewart DR, Schmidt ML, Donninger H, Clark GJ. The RASSF1A Tumor Suppressor Binds the RasGAP DAB2IP and Modulates RAS Activation in Lung Cancer. Cancers (Basel) 2020; 12:cancers12123807. [PMID: 33348649 PMCID: PMC7766191 DOI: 10.3390/cancers12123807] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 11/13/2020] [Accepted: 12/10/2020] [Indexed: 12/30/2022] Open
Abstract
Simple Summary The RASSF1A tumor suppressor can serve as a pro-apoptotic effector of the K-RAS oncoprotein. It is frequently inactivated epigenetically in lung cancer, and genetic inactivation of RASSF1A in transgenic mice enhances the ability of mutant K-RAS to promote tumorigenesis. Here we show that RASSF1A complexes with and stabilizes the protein DAB2IP. DAB2IP is a tumor suppressor itself and acts, in part, as a negative regulator (GAP) for RAS. Thus, loss of RASSF1A results in the reduced expression of DAB2IP, which promotes the activation of wild type RAS. Therefore, RASSF1A negative cells are likely to show enhanced RAS activity. This may be the first example of a RAS effector being able to back-regulate RAS activity. Abstract Lung cancer is the leading cause of cancer-related death worldwide. Lung cancer is commonly driven by mutations in the RAS oncogenes, the most frequently activated oncogene family in human disease. RAS-induced tumorigenesis is inhibited by the tumor suppressor RASSF1A, which induces apoptosis in response to hyperactivation of RAS. RASSF1A expression is suppressed in cancer at high rates, primarily owing to promoter hypermethylation. Recent reports have shown that loss of RASSF1A expression uncouples RAS from apoptotic signaling in vivo, thereby enhancing tumor aggressiveness. Moreover, a concomitant upregulation of RAS mitogenic signaling upon RASSF1A loss has been observed, suggesting RASSF1A may directly regulate RAS activation. Here, we present the first mechanistic evidence for control of RAS activation by RASSF1A. We present a novel interaction between RASSF1A and the Ras GTPase Activating Protein (RasGAP) DAB2IP, an important negative regulator of RAS. Using shRNA-mediated knockdown and stable overexpression approaches, we demonstrate that RASSF1A upregulates DAB2IP protein levels in NSCLC cells. Suppression of RASSF1A and subsequent downregulation of DAB2IP enhances GTP loading onto RAS, thus increasing RAS mitogenic signaling in both mutant- and wildtype-RAS cells. Moreover, co-suppression of RASSF1A and DAB2IP significantly enhances in vitro and in vivo growth of wildtype-RAS cells. Tumors expressing wildtype RAS, therefore, may still suffer from hyperactive RAS signaling when RASSF1A is downregulated. This may render them susceptible to the targeted RAS inhibitors currently in development.
Collapse
Affiliation(s)
- Desmond R. Harrell Stewart
- Department of Pharmacology & Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA; (D.R.H.S.); (M.L.S.)
| | - M. Lee Schmidt
- Department of Pharmacology & Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA; (D.R.H.S.); (M.L.S.)
| | - Howard Donninger
- Department of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA;
| | - Geoffrey J. Clark
- Department of Pharmacology & Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA; (D.R.H.S.); (M.L.S.)
- Correspondence:
| |
Collapse
|
4
|
Li C, Donninger H, Eaton J, Yaddanapudi K. Regulatory Role of Immune Cell-Derived Extracellular Vesicles in Cancer: The Message Is in the Envelope. Front Immunol 2020; 11:1525. [PMID: 32765528 PMCID: PMC7378739 DOI: 10.3389/fimmu.2020.01525] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Accepted: 06/09/2020] [Indexed: 12/28/2022] Open
Abstract
Extracellular vesicles (EVs) are a heterogenous group of membrane-surrounded structures. Besides serving as a harbor for the unwanted material exocytosed by cells, EVs play a critical role in conveying intact protein, genetic, and lipid contents that are important for intercellular communication. EVs, broadly comprised of microvesicles and exosomes, are released to the extracellular environment from nearly all cells either via shedding from the plasma membrane or by originating from the endosomal system. Exosomes are 40–150 nm, endosome-derived small EVs (sEVs) that are released by cells into the extracellular environment. This review focuses on the biological properties of immune cell-derived sEVs, including composition and cellular targeting and mechanisms by which these immune cell-derived sEVs influence tumor immunity either by suppressing or promoting tumor growth, are discussed. The final section of this review discusses how the biological properties of immune cell-derived sEVs can be manipulated to improve their immunogenicity.
Collapse
Affiliation(s)
- Chi Li
- Experimental Therapeutics Group, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, United States.,Department of Medicine, University of Louisville, Louisville, KY, United States
| | - Howard Donninger
- Experimental Therapeutics Group, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, United States.,Department of Medicine, University of Louisville, Louisville, KY, United States
| | - John Eaton
- Department of Medicine, University of Louisville, Louisville, KY, United States.,Immuno-Oncology Group, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, United States
| | - Kavitha Yaddanapudi
- Immuno-Oncology Group, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, United States.,Division of Immunotherapy, Department of Surgery, University of Louisville, Louisville, KY, United States.,Department of Microbiology and Immunology, University of Louisville, Louisville, KY, United States
| |
Collapse
|
5
|
He L, Wei X, Ma X, Yin X, Song M, Donninger H, Yaddanapudi K, McClain CJ, Zhang X. Simultaneous Quantification of Nucleosides and Nucleotides from Biological Samples. J Am Soc Mass Spectrom 2019; 30:987-1000. [PMID: 30847833 PMCID: PMC6520184 DOI: 10.1007/s13361-019-02140-7] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2018] [Revised: 01/17/2019] [Accepted: 01/17/2019] [Indexed: 05/16/2023]
Abstract
We report a reverse phase chromatography mass spectrometry (LC-MS) method for simultaneous quantification of nucleosides and nucleotides from biological samples, where compound identification was achieved by a tier-wise approach and compound quantification was achieved via external calibration. A total of 65 authentic standards of nucleosides and nucleotides were used for the platform development. The limit of detection (LOD) of those compounds ranged from 0.05 nmol/L to 1.25 μmol/L, and their limit of quantification (LOQ) ranged from 0.10 nmol/L to 2.50 μmol/L. Using the developed method, nucleosides and nucleotides from human plasma, human urine, and rat liver were quantified. Seventy-nine nucleosides and nucleotides were identified from human urine and 28 of them were quantified with concentrations of 13.0 nmol/L-151 μmol/L. Fifty-five nucleosides and nucleotides were identified from human plasma and 22 of them were quantified with concentrations of 1.21 nmol/L-8.54 μmol/L. Fifty-one nucleosides and nucleotides were identified from rat liver and 23 were quantified with concentrations of 1.03 nmol/L-31.7 μmol/L. These results demonstrate that the developed method can be used to investigate the concentration change of nucleosides and nucleotides in biological samples for the purposes of biomarker discovery or elucidation of disease mechanisms.
Collapse
Affiliation(s)
- Liqing He
- Department of Chemistry, University of Louisville, 2210 South Brook Street, Louisville, KY, 40208, USA.
- Alcohol Research Center, University of Louisville, Louisville, KY, 40208, USA.
- Hepatobiology and Toxicology Program, University of Louisville, Louisville, KY, 40208, USA.
- Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY, 40208, USA.
| | - Xiaoli Wei
- Department of Chemistry, University of Louisville, 2210 South Brook Street, Louisville, KY, 40208, USA
- Alcohol Research Center, University of Louisville, Louisville, KY, 40208, USA
- Hepatobiology and Toxicology Program, University of Louisville, Louisville, KY, 40208, USA
- Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY, 40208, USA
| | - Xipeng Ma
- Department of Chemistry, University of Louisville, 2210 South Brook Street, Louisville, KY, 40208, USA
- Alcohol Research Center, University of Louisville, Louisville, KY, 40208, USA
- Hepatobiology and Toxicology Program, University of Louisville, Louisville, KY, 40208, USA
- Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY, 40208, USA
| | - Xinmin Yin
- Department of Chemistry, University of Louisville, 2210 South Brook Street, Louisville, KY, 40208, USA
- Alcohol Research Center, University of Louisville, Louisville, KY, 40208, USA
- Hepatobiology and Toxicology Program, University of Louisville, Louisville, KY, 40208, USA
- Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY, 40208, USA
| | - Ming Song
- Alcohol Research Center, University of Louisville, Louisville, KY, 40208, USA
- Hepatobiology and Toxicology Program, University of Louisville, Louisville, KY, 40208, USA
- Department of Medicine, University of Louisville, Louisville, KY, 40208, USA
| | - Howard Donninger
- Department of Medicine, University of Louisville, Louisville, KY, 40208, USA
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY, 40208, USA
| | - Kavitha Yaddanapudi
- Department of Medicine, University of Louisville, Louisville, KY, 40208, USA
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY, 40208, USA
| | - Craig J McClain
- Alcohol Research Center, University of Louisville, Louisville, KY, 40208, USA
- Hepatobiology and Toxicology Program, University of Louisville, Louisville, KY, 40208, USA
- Department of Medicine, University of Louisville, Louisville, KY, 40208, USA
- Department of Pharmacology & Toxicology, University of Louisville, Louisville, KY, 40208, USA
- Robley Rex Louisville VAMC, Louisville, KY, 40292, USA
| | - Xiang Zhang
- Department of Chemistry, University of Louisville, 2210 South Brook Street, Louisville, KY, 40208, USA
- Alcohol Research Center, University of Louisville, Louisville, KY, 40208, USA
- Hepatobiology and Toxicology Program, University of Louisville, Louisville, KY, 40208, USA
- Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY, 40208, USA
- Department of Pharmacology & Toxicology, University of Louisville, Louisville, KY, 40208, USA
| |
Collapse
|
6
|
Harrell Stewart D, Hobbing K, Schmidt ML, Donninger H, Clark GJ. The role of RASSF proteins in modulating RAS driven lung tumors in vivo. J Thorac Dis 2019; 11:S1436-S1437. [PMID: 31245154 PMCID: PMC6560612 DOI: 10.21037/jtd.2019.03.60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2019] [Accepted: 03/14/2019] [Indexed: 04/16/2024]
Affiliation(s)
| | - Katherine Hobbing
- Department of Pharmacology & Toxicology, University of Louisville, Louisville, KY, USA
| | - M. Lee Schmidt
- Department of Pharmacology & Toxicology, University of Louisville, Louisville, KY, USA
| | - Howard Donninger
- Department of Medicine, University of Louisville, Louisville, KY, USA
| | - Geoffrey J. Clark
- Department of Pharmacology & Toxicology, University of Louisville, Louisville, KY, USA
| |
Collapse
|
7
|
Schmidt ML, Hobbing KR, Donninger H, Clark GJ. RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis. Cancer Res 2018; 78:2614-2623. [PMID: 29735543 DOI: 10.1158/0008-5472.can-17-2466] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Revised: 01/26/2018] [Accepted: 03/01/2018] [Indexed: 12/30/2022]
Abstract
Mutant K-RAS has been shown to have both tumor-promoting and -suppressing functions, and growing evidence suggests that the RASSF family of tumor suppressors can act as RAS apoptosis and senescence effectors. It has been hypothesized that inactivation of the RASSF1A tumor suppressor facilitates K-RAS-mediated transformation by uncoupling it from apoptotic pathways such as the Hippo pathway. In human lung tumors, combined activation of K-RAS and inactivation of RASSF1A is closely associated with the development of the most aggressive and worst prognosis tumors. Here, we describe the first transgenic mouse model for activation of K-RAS in the lung in a RASSF1A-defective background. RASSF1A deficiency profoundly enhanced the development of K-RAS-driven lung tumors in vivo Analysis of these tumors showed loss of RASSF1A-uncoupled RAS from the proapoptotic Hippo pathway as expected. We also observed an upregulation of AKT and RALGEF signaling in the RASSF1A- tumors. Heterozygosity of RASSF1A alone mimicked many of the effects of RAS activation on mitogenic signaling in lung tissue, yet no tumors developed, indicating that nonstandard Ras signaling pathways may be playing a key role in tumor formation in vivo In addition, we observed a marked increase in inflammation and IL6 production in RASSF1A-deficient tumors. Thus, RASSF1A loss profoundly affects RAS-driven lung tumorigenesis and mitogenic signaling in vivo Deregulation of inflammatory pathways due to loss of RASSF1A may be essential for RAS-mediated tumorigenesis. These results may have considerable ramifications for future targeted therapy against RAS+/RASSF1A- tumors.Significance: A transgenic mouse model shows that suppression of RASSF1A dramatically enhances Ras-driven tumorigenesis and alters Ras signaling pathway activity.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/10/2614/F1.large.jpg Cancer Res; 78(10); 2614-23. ©2018 AACR.
Collapse
Affiliation(s)
- M Lee Schmidt
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky
| | - Katharine R Hobbing
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky
| | - Howard Donninger
- Department of Medicine, University of Louisville, Louisville, Kentucky
| | - Geoffrey J Clark
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky.
| |
Collapse
|
8
|
Barnoud T, Schmidt ML, Donninger H, Clark GJ. The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence. Cancer Lett 2017; 400:30-36. [PMID: 28455242 PMCID: PMC5502528 DOI: 10.1016/j.canlet.2017.04.030] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2017] [Revised: 04/18/2017] [Accepted: 04/19/2017] [Indexed: 12/14/2022]
Abstract
The Ras genes are the most frequently mutated oncogenes in human cancer. However, Ras biology is quite complex. While Ras promotes tumorigenesis by regulating numerous growth promoting pathways, activated Ras can paradoxically also lead to cell cycle arrest, death, and Oncogene-Induced Senescence (OIS). OIS is thought to be a critical pathway that serves to protect cells against aberrant Ras signaling. Multiple reports have highlighted the importance of the p53 and Rb tumor suppressors in Ras mediated OIS. However, until recently, the molecular mechanisms connecting Ras to these proteins remained unknown. The RASSF family of tumor suppressors has recently been identified as direct effectors of Ras. One of these members, NORE1A (RASSF5), may be the missing link between Ras-induced senescence and the regulation of p53 and Rb. This occurs both quantitatively, by promoting protein stability, as well as qualitatively via promoting critical pro-senescent post-translational modifications. Here we review the mechanisms by which NORE1A can activate OIS as a barrier against Ras-mediated transformation, and how this could lead to improved therapeutic strategies against cancers having lost NORE1A expression.
Collapse
Affiliation(s)
- Thibaut Barnoud
- Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia PA 19104, USA
| | - M Lee Schmidt
- Department of Pharmacology and Toxicology, University of Louisville, KY 40202, USA
| | | | - Geoffrey J Clark
- Department of Pharmacology and Toxicology, University of Louisville, KY 40202, USA.
| |
Collapse
|
9
|
Arora P, Basu A, Schmidt ML, Clark GJ, Donninger H, Nichols DB, Calvisi DF, Kaushik-Basu N. Nonstructural protein 5B promotes degradation of the NORE1A tumor suppressor to facilitate hepatitis C virus replication. Hepatology 2017; 65:1462-1477. [PMID: 28090674 PMCID: PMC5397368 DOI: 10.1002/hep.29049] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Revised: 01/06/2017] [Accepted: 01/09/2017] [Indexed: 12/16/2022]
Abstract
UNLABELLED Hepatitis C virus (HCV) infection is a common risk factor for the development of liver cancer. The molecular mechanisms underlying this effect are only partially understood. Here, we show that the HCV protein, nonstructural protein (NS) 5B, directly binds to the tumor suppressor, NORE1A (RASSF5), and promotes its proteosomal degradation. In addition, we show that NORE1A colocalizes to sites of HCV viral replication and suppresses the replication process. Thus, NORE1A has antiviral activity, which is specifically antagonized by NS5B. Moreover, the suppression of NORE1A protein levels correlated almost perfectly with elevation of Ras activity in primary human samples. Therefore, NORE1A inactivation by NS5B may be essential for maximal HCV replication and may make a major contribution to HCV-induced liver cancer by shifting Ras signaling away from prosenescent/proapoptotic signaling pathways. CONCLUSION HCV uses NS5B to specifically suppress NORE1A, facilitating viral replication and elevated Ras signaling. (Hepatology 2017;65:1462-1477).
Collapse
Affiliation(s)
- Payal Arora
- Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA
| | - Amartya Basu
- Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA
| | - M. Lee Schmidt
- Dept. Pharmacology and Toxicology, University of Louisville, Rm 417, CTRB 505, S. Hancock St., Louisville, KY 40202, USA
| | - Geoffrey J. Clark
- Dept. Pharmacology and Toxicology, University of Louisville, Rm 417, CTRB 505, S. Hancock St., Louisville, KY 40202, USA,To whom correspondence should be addressed: ,
| | - Howard Donninger
- Dept. Pharmacology and Toxicology, University of Louisville, Rm 417, CTRB 505, S. Hancock St., Louisville, KY 40202, USA
| | - Daniel B. Nichols
- Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA,Department of Biological Sciences, Seton Hall University, South Orange, NJ 07079, USA
| | - Diego F. Calvisi
- Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
| | - Neerja Kaushik-Basu
- Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA,To whom correspondence should be addressed: ,
| |
Collapse
|
10
|
Donninger H, Schmidt ML, Mezzanotte J, Barnoud T, Clark GJ. Ras signaling through RASSF proteins. Semin Cell Dev Biol 2016; 58:86-95. [PMID: 27288568 DOI: 10.1016/j.semcdb.2016.06.007] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Accepted: 06/07/2016] [Indexed: 12/16/2022]
Abstract
There are six core RASSF family proteins that contain conserved Ras Association domains and may serve as Ras effectors. They lack intrinsic enzymatic activity and appear to function as scaffolding and localization molecules. While initially being associated with pro-apoptotic signaling pathways such as Bax and Hippo, it is now clear that they can also connect Ras to a surprisingly broad range of signaling pathways that control senescence, inflammation, autophagy, DNA repair, ubiquitination and protein acetylation. Moreover, they may be able to impact the activation status of pro-mitogenic Ras effector pathways, such as the Raf pathway. The frequent epigenetic inactivation of RASSF genes in human tumors disconnects Ras from pro-death signaling systems, enhancing Ras driven transformation and metastasis. The best characterized members are RASSF1A and RASSF5 (NORE1A).
Collapse
Affiliation(s)
- Howard Donninger
- Department of Medicine, University of Louisville, KY, 40202, USA
| | - M Lee Schmidt
- Department of Pharmacoloxy and Toxicology, University of Louisville, KY, 40202, USA
| | - Jessica Mezzanotte
- Department of Biochemistry and Molecular Genetics, Molecular Targets Program, J.G Brown Cancer Center, University of Louisville, Louisville, KY, 40202, USA
| | - Thibaut Barnoud
- Department of Biochemistry and Molecular Genetics, Molecular Targets Program, J.G Brown Cancer Center, University of Louisville, Louisville, KY, 40202, USA
| | - Geoffrey J Clark
- Department of Pharmacoloxy and Toxicology, University of Louisville, KY, 40202, USA.
| |
Collapse
|
11
|
Barnoud T, Wilkey DW, Merchant ML, Clark JA, Donninger H. Proteomics Analysis Reveals Novel RASSF2 Interaction Partners. Cancers (Basel) 2016; 8:cancers8030037. [PMID: 26999212 PMCID: PMC4810121 DOI: 10.3390/cancers8030037] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2016] [Revised: 02/18/2016] [Accepted: 03/09/2016] [Indexed: 12/30/2022] Open
Abstract
RASSF2 is a tumor suppressor that shares homology with other Ras-association domain (RASSF) family members. It is a powerful pro-apoptotic K-Ras effector that is frequently inactivated in many human tumors. The exact mechanism by which RASSF2 functions is not clearly defined, but it likely acts as a scaffolding protein, modulating the activity of other pro-apoptotic effectors, thereby regulating and integrating tumor suppressor pathways. However, only a limited number of RASSF2 interacting partners have been identified to date. We used a proteomics based approach to identify additional RASSF2 interactions, and thereby gain a better insight into the mechanism of action of RASSF2. We identified several proteins, including C1QBP, Vimentin, Protein phosphatase 1G and Ribonuclease inhibitor that function in diverse biological processes, including protein post-translational modifications, epithelial-mesenchymal transition, cell migration and redox homeostasis, which have not previously been reported to interact with RASSF2. We independently validated two of these novel interactions, C1QBP and Vimentin and found that the interaction with C1QBP was enhanced by K-Ras whereas, interestingly, the Vimentin interaction was reduced by K-Ras. Additionally, RASSF2/K-Ras regulated the acetylation of Vimentin. Our data thus reveal novel mechanisms by which RASSF2 may exert its functions, several of which may be Ras-regulated.
Collapse
Affiliation(s)
- Thibaut Barnoud
- Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY 40202, USA.
| | - Daniel W Wilkey
- Department of Medicine, James Graham Brown Cancer Center, Molecular Targets Program, University of Louisville, Louisville, KY 40202, USA.
| | - Michael L Merchant
- Department of Medicine, James Graham Brown Cancer Center, Molecular Targets Program, University of Louisville, Louisville, KY 40202, USA.
| | - Jennifer A Clark
- Department of Medicine, James Graham Brown Cancer Center, Molecular Targets Program, University of Louisville, Louisville, KY 40202, USA.
| | - Howard Donninger
- Department of Medicine, James Graham Brown Cancer Center, Molecular Targets Program, University of Louisville, Louisville, KY 40202, USA.
| |
Collapse
|
12
|
Abstract
Although Ras is a potent oncogene in human tumors it has the paradoxical ability to promote Oncogene Induced Senescence (OIS). This appears to serve as a major barrier to Ras driven transformation in vivo. The signaling pathways used by Ras to promote senescence remain relatively poorly understood, but appear to invoke both the p53 and the Rb master tumor suppressors. Exactly how Ras communicates with p53 and Rb has remained something of a puzzle. NORE1A is a direct Ras effector that is frequently downregulated in human tumors. We have now found that it serves as a powerful Ras senescence effector. Moreover, we have defined signaling mechanisms that allows Ras to control both p53 and Rb post-translational modifications via the NORE1A scaffolding molecule. Indeed, NORE1A can be detected in complex with both p53 and Rb. Thus, by coupling Ras to both tumor suppressors, NORE1A forms a major component of the Ras senescence machinery and serves as the missing link between Ras and p53/Rb.
Collapse
Affiliation(s)
- Howard Donninger
- a Department of Medicine , J.G Brown Cancer Center, Molecular Targets Group, University of Louisville , Louisville , KY 40202
| | - Thibaut Barnoud
- b Department of Biochemistry and Molecular Genetics , J.G Brown Cancer Center, Molecular Targets Group, University of Louisville , Louisville , KY 40202 and
| | - Geoffrey J Clark
- c Department of Pharmacology and Toxicology , J.G Brown Cancer Center, Molecular Targets Group, University of Louisville , Louisville , KY 40202
| |
Collapse
|
13
|
Abstract
Mutations in the Ras oncogene are one of the most frequent events in human cancer. Although Ras regulates numerous growth-promoting pathways to drive transformation, it can paradoxically promote an irreversible cell cycle arrest known as oncogene-induced senescence. Although senescence has clearly been implicated as a major defense mechanism against tumorigenesis, the mechanisms by which Ras can promote such a senescent phenotype remain poorly defined. We have shown recently that the Ras death effector NORE1A plays a critical role in promoting Ras-induced senescence and connects Ras to the regulation of the p53 tumor suppressor. We now show that NORE1A also connects Ras to the regulation of a second major prosenescent tumor suppressor, the retinoblastoma (Rb) protein. We show that Ras induces the formation of a complex between NORE1A and the phosphatase PP1A, promoting the activation of the Rb tumor suppressor by dephosphorylation. Furthermore, suppression of Rb reduces NORE1A senescence activity. These results, together with our previous findings, suggest that NORE1A acts as a critical tumor suppressor node, linking Ras to both the p53 and the Rb pathways to drive senescence.
Collapse
Affiliation(s)
| | | | - Geoffrey J Clark
- Pharmacology and Toxicology, James Graham Brown Cancer Center, Molecular Targets Program, University of Louisville, Louisville, Kentucky 40202
| |
Collapse
|
14
|
Scherzer MT, Waigel S, Donninger H, Arumugam V, Zacharias W, Clark G, Siskind LJ, Soucy P, Beverly L. Fibroblast-Derived Extracellular Matrices: An Alternative Cell Culture System That Increases Metastatic Cellular Properties. PLoS One 2015; 10:e0138065. [PMID: 26371754 PMCID: PMC4570771 DOI: 10.1371/journal.pone.0138065] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Accepted: 08/26/2015] [Indexed: 12/31/2022] Open
Abstract
Poor survival rates from lung cancer can largely be attributed to metastatic cells that invade and spread throughout the body. The tumor microenvironment (TME) is composed of multiple cell types, as well as non-cellular components. The TME plays a critical role in the development of metastatic cancers by providing migratory cues and changing the properties of the tumor cells. The Extracellular Matrix (ECM), a main component of the TME, has been shown to change composition during tumor progression, contributing to cancer cell invasion and survival away from the primary cancer site. Although the ECM is well-known to influence the fate of tumor progression, little is known about the molecular mechanisms that are affected by the cancer cell-ECM interactions. It is imperative that these mechanisms are elucidated in order to properly understand and prevent lung cancer dissemination. However, common in vitro studies do not incorporate these interactions into everyday cell culture assays. We have adopted a model that examines decellularized human fibroblast-derived ECM as a 3-dimensional substrate for growth of lung adenocarcinoma cell lines. Here, we have characterized the effect of fibroblast-derived matrices on the properties of various lung-derived epithelial cell lines, including cancerous and non-transformed cells. This work highlights the significance of the cell-ECM interaction and its requirement for incorporation into in vitro experiments. Implementation of a fibroblast-derived ECM as an in vitro technique will provide researchers with an important factor to manipulate to better recreate and study the TME.
Collapse
Affiliation(s)
- Michael T. Scherzer
- J. G. Brown Cancer Center, University of Louisville, Louisville, Kentucky, 40202, United States of America
- Department of Bioengineering, University of Louisville, Louisville, Kentucky, 40202, United States of America
| | - Sabine Waigel
- J. G. Brown Cancer Center, University of Louisville, Louisville, Kentucky, 40202, United States of America
| | - Howard Donninger
- J. G. Brown Cancer Center, University of Louisville, Louisville, Kentucky, 40202, United States of America
- Department of Medicine, University of Louisville, Louisville, Kentucky, 40202, United States of America
| | - Vennila Arumugam
- J. G. Brown Cancer Center, University of Louisville, Louisville, Kentucky, 40202, United States of America
| | - Wolfgang Zacharias
- J. G. Brown Cancer Center, University of Louisville, Louisville, Kentucky, 40202, United States of America
- Department of Medicine, University of Louisville, Louisville, Kentucky, 40202, United States of America
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, 40202, United States of America
| | - Geoffrey Clark
- J. G. Brown Cancer Center, University of Louisville, Louisville, Kentucky, 40202, United States of America
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, 40202, United States of America
| | - Leah J. Siskind
- J. G. Brown Cancer Center, University of Louisville, Louisville, Kentucky, 40202, United States of America
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, 40202, United States of America
| | - Patricia Soucy
- Department of Bioengineering, University of Louisville, Louisville, Kentucky, 40202, United States of America
| | - Levi Beverly
- J. G. Brown Cancer Center, University of Louisville, Louisville, Kentucky, 40202, United States of America
- Department of Bioengineering, University of Louisville, Louisville, Kentucky, 40202, United States of America
- Department of Medicine, University of Louisville, Louisville, Kentucky, 40202, United States of America
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, 40202, United States of America
- * E-mail:
| |
Collapse
|
15
|
Donninger H, Hobbing K, Schmidt ML, Walters E, Rund L, Schook L, Clark GJ. A porcine model system of BRCA1 driven breast cancer. Front Genet 2015; 6:269. [PMID: 26379698 PMCID: PMC4548227 DOI: 10.3389/fgene.2015.00269] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2015] [Accepted: 08/06/2015] [Indexed: 12/19/2022] Open
Abstract
BRCA1 is a breast and ovarian tumor suppressor. Hereditary mutations in BRCA1 result in a predisposition to breast cancer, and BRCA1 expression is down-regulated in ~30% of sporadic cases. The function of BRCA1 remains poorly understood, but it appears to play an important role in DNA repair and the maintenance of genetic stability. Mouse models of BRCA1 deficiency have been developed in an attempt to understand the role of the gene in vivo. However, the subtle nature of BRCA1 function and the well-known discrepancies between human and murine breast cancer biology and genetics may limit the utility of mouse systems in defining the function of BRCA1 in cancer and validating the development of novel therapeutics for breast cancer. In contrast to mice, pig biological systems, and cancer genetics appear to more closely resemble their human counterparts. To determine if BRCA1 inactivation in pig cells promotes their transformation and may serve as a model for the human disease, we developed an immortalized porcine breast cell line and stably inactivated BRCA1 using miRNA. The cell line developed characteristics of breast cancer stem cells and exhibited a transformed phenotype. These results validate the concept of using pigs as a model to study BRCA1 defects in breast cancer and establish the first porcine breast tumor cell line.
Collapse
Affiliation(s)
- Howard Donninger
- Department of Medicine, James Graham Brown Cancer Center, University of Louisville Louisville, KY, USA
| | - Katharine Hobbing
- Department of Pharmacology and Toxicology, James Graham Brown Cancer Center, University of Louisville Louisville, KY, USA
| | - M L Schmidt
- Department of Biochemistry, University of Louisville Louisville, KY, USA
| | - Eric Walters
- Division of Animal Sciences, National Swine Resource and Research Center, University of Missouri Columbia, MO, USA
| | - Laurie Rund
- Department of Animal Sciences, University of Illinois at Urbana-Champaign Urbana, IL, USA
| | - Larry Schook
- Department of Animal Sciences, University of Illinois at Urbana-Champaign Urbana, IL, USA
| | - Geoffrey J Clark
- Department of Pharmacology and Toxicology, James Graham Brown Cancer Center, University of Louisville Louisville, KY, USA
| |
Collapse
|
16
|
Abstract
RAS-induced senescence is a protective mechanism to avoid unrestricted cell growth due to aberrant mitogenic signals; however, the exact mechanism by which RAS induces senescence is not known. We recently identified a novel pathway linking RAS to p53 via NORE1A and HIPK2 that mechanistically explains how Ras induces senescence.
Collapse
Affiliation(s)
- Howard Donninger
- Department of Medicine, J.G Brown Cancer Center, Molecular Targets Group, University of Louisville , Louisville, KY, USA
| | - Geoffrey J Clark
- Department of Pharmacology and Toxicology, J.G Brown Cancer Center, Molecular Targets Group, University of Louisville , Louisville, KY, USA
| |
Collapse
|
17
|
Donninger H, Calvisi DF, Barnoud T, Clark J, Schmidt ML, Vos MD, Clark GJ. NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2. ACTA ACUST UNITED AC 2015; 208:777-89. [PMID: 25778922 PMCID: PMC4362463 DOI: 10.1083/jcb.201408087] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
NORE1A is a Ras senescence effector that modulates HIPK2-dependent posttranslational modifications of p53. The Ras oncoprotein is a key driver of cancer. However, Ras also provokes senescence, which serves as a major barrier to Ras-driven transformation. Ras senescence pathways remain poorly characterized. NORE1A is a novel Ras effector that serves as a tumor suppressor. It is frequently inactivated in tumors. We show that NORE1A is a powerful Ras senescence effector and that down-regulation of NORE1A suppresses senescence induction by Ras and enhances Ras transformation. We show that Ras induces the formation of a complex between NORE1A and the kinase HIPK2, enhancing HIPK2 association with p53. HIPK2 is a tumor suppressor that can induce either proapoptotic or prosenescent posttranslational modifications of p53. NORE1A acts to suppress its proapoptotic phosphorylation of p53 but enhance its prosenescent acetylation of p53. Thus, we identify a major new Ras signaling pathway that links Ras to the control of specific protein acetylation and show how NORE1A allows Ras to qualitatively modify p53 function to promote senescence.
Collapse
Affiliation(s)
- Howard Donninger
- Department of Medicine, Department of Biochemistry and Molecular Biology, Department of Pharmacology and Toxicology, J.G. Brown Cancer Center, Molecular Targets Group, University of Louisville, Louisville, KY 40202
| | | | - Thibaut Barnoud
- Department of Medicine, Department of Biochemistry and Molecular Biology, Department of Pharmacology and Toxicology, J.G. Brown Cancer Center, Molecular Targets Group, University of Louisville, Louisville, KY 40202
| | - Jennifer Clark
- Department of Medicine, Department of Biochemistry and Molecular Biology, Department of Pharmacology and Toxicology, J.G. Brown Cancer Center, Molecular Targets Group, University of Louisville, Louisville, KY 40202
| | - M Lee Schmidt
- Department of Medicine, Department of Biochemistry and Molecular Biology, Department of Pharmacology and Toxicology, J.G. Brown Cancer Center, Molecular Targets Group, University of Louisville, Louisville, KY 40202
| | - Michele D Vos
- Research Analysis and Evaluation Branch, National Cancer Institute, Rockville, MD 20850
| | - Geoffrey J Clark
- Department of Medicine, Department of Biochemistry and Molecular Biology, Department of Pharmacology and Toxicology, J.G. Brown Cancer Center, Molecular Targets Group, University of Louisville, Louisville, KY 40202
| |
Collapse
|
18
|
Donninger H, Calvisi D, Barnoud T, Schmidt ML, Clark GJ. Abstract A06: NORE1A is a double-barreled Ras senescence effector linking Ras to p53 and Rb. Mol Cancer Res 2014. [DOI: 10.1158/1557-3125.rasonc14-a06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
In addition to driving growth and transformation, activated forms of Ras are potent inducers of oncogene induced senescence (OIS). OIS appears to be a major barrier that must be overcome to permit Ras driven tumorigenesis. The signaling pathways utilized by Ras to induce senescence, and how they are subverted during tumor development remain poorly characterized.
NORE1A is a member of the RASSF family of tumor suppressors. It binds directly to activated Ras via the Ras effector domain and acts as a Ras death effector. Frequent loss of NORE1A expression is observed in many tumor types and hereditary genetic defects in NORE1A predispose carriers to cancer. We have found that NORE1A can connect Ras to the induction of p21CIP1 and cell cycle arrest. Therefore, we sought to determine if NORE1A might play a role in Ras induced senescence.
We now show that NORE1A is a potent mediator of Ras induced senescence. Knockdown of NORE1A suppresses the ability of Ras to induce senescence in multiple cell systems and enhances Ras driven transformation. We have identified two novel signaling pathways activated by Ras/NORE1A. First, NORE1A forms a Ras regulated, endogenous complex with the kinase HIPK2. HIPK2 can phosphorylate p53 to induce apoptosis or recruit acetyltransferases to acetylate p53 to induce senescence signaling. NORE1A suppresses HIPK2 apoptotic post-translational modifications of p53 but activates pro-senescence post-translational modifications. NORE1A also binds and destabilizes mdm2 to enhance the stability of nuclear p53. Primary human tumors show a close correlation between the expression levels of NORE1A and acetylated p53.
In addition to p53, we show that NORE1A also links Ras to the regulation of Retinoblastoma (Rb) protein. NORE1A promotes a potent, Ras dependent stabilization of the Rb protein. It also promotes dephosphorylation of RB, an activating event.
Thus, NORE1A is a double-barreled Ras senescence effector which connects Ras to two of the most important senescence regulating tumor suppressors in the cell.
Loss of NORE1A activity in tumors is usually due to epigenetic inactivation or aberrant protein degradation by calpains. Both of these mechanisms, in principal, may be subject to clinical intervention to restore NORE1A function. This may provide a novel approach to antagonizing Ras driven tumors.
Citation Format: Howard Donninger, Diego Calvisi, Thibaut Barnoud, M. Lee Schmidt, Geoffrey J. Clark. NORE1A is a double-barreled Ras senescence effector linking Ras to p53 and Rb. [abstract]. In: Proceedings of the AACR Special Conference on RAS Oncogenes: From Biology to Therapy; Feb 24-27, 2014; Lake Buena Vista, FL. Philadelphia (PA): AACR; Mol Cancer Res 2014;12(12 Suppl):Abstract nr A06. doi: 10.1158/1557-3125.RASONC14-A06
Collapse
Affiliation(s)
| | - Diego Calvisi
- 2Ernst-Moritz-Arndt-Universität, Griefswald, Germany
| | | | | | | |
Collapse
|
19
|
Donninger H, Clark JA, Monaghan MK, Schmidt ML, Vos M, Clark GJ. Cell cycle restriction is more important than apoptosis induction for RASSF1A protein tumor suppression. J Biol Chem 2014; 289:31287-95. [PMID: 25225292 DOI: 10.1074/jbc.m114.609537] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
The Ras association domain family protein 1A (RASSF1A) is arguably one of the most frequently inactivated tumor suppressors in human cancer. RASSF1A modulates apoptosis via the Hippo and Bax pathways but also modulates the cell cycle. In part, cell cycle regulation appears to be dependent upon the ability of RASSF1A to complex with microtubules and regulate their dynamics. Which property of RASSF1A, apoptosis induction or microtubule regulation, is responsible for its tumor suppressor function is not known. We have identified a short conserved motif that is essential for the binding of RASSF family proteins with microtubule-associated proteins. By making a single point mutation in the motif, we were able to generate a RASSF1A variant that retains wild-type apoptotic properties but completely loses the ability to bind microtubule-associated proteins and complex with microtubules. Comparison of this mutant to wild-type RASSF1A showed that, despite retaining its proapoptotic properties, the mutant was completely unable to induce cell cycle arrest or suppress the tumorigenic phenotype. Therefore, it appears that the cell cycle/microtubule effects of RASSF1A are key to its tumor suppressor function rather than its apoptotic effects.
Collapse
Affiliation(s)
| | | | | | | | - Michele Vos
- the Cell and Cancer Biology Branch, NCI, National Institutes of Health, Rockville, Maryland 20850
| | - Geoffrey J Clark
- Pharmacology and Toxicology, James Graham Brown Cancer Center, Molecular Targets Program, University of Louisville, Louisville, Kentucky 40202 and
| |
Collapse
|
20
|
Abstract
Ras is the most frequently activated oncogene found in human cancer, but its mechanisms of action remain only partially understood. Ras activates multiple signaling pathways to promote transformation. However, Ras can also exhibit a potent ability to induce growth arrest and death. NORE1A (RASSF5) is a direct Ras effector that acts as a tumor suppressor by promoting apoptosis and cell cycle arrest. Expression of NORE1A is frequently lost in human tumors, and its mechanism of action remains unclear. Here we show that NORE1A forms a direct, Ras-regulated complex with β-TrCP, the substrate recognition component of the SCF(β-TrCP) ubiquitin ligase complex. This interaction allows Ras to stimulate the ubiquitin ligase activity of SCF(β-TrCP) toward its target β-catenin, resulting in degradation of β-catenin by the 26 S proteasome. However, the action of Ras/NORE1A/β-TrCP is substrate-specific because IκB, another substrate of SCF(β-TrCP), is not sensitive to NORE1A-promoted degradation. We identify a completely new signaling mechanism for Ras that allows for the specific regulation of SCF(β-TrCP) targets. We show that the NORE1A levels in a cell may dictate the effects of Ras on the Wnt/β-catenin pathway. Moreover, because NORE1A expression is frequently impaired in tumors, we provide an explanation for the observation that β-TrCP can act as a tumor suppressor or an oncogene in different cell systems.
Collapse
Affiliation(s)
- M Lee Schmidt
- From the Molecular Targets Group, James Graham Brown Cancer Center, Departments of Biochemistry and Molecular Biology
| | | | - Geoffrey J Clark
- Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky 40202
| |
Collapse
|
21
|
Yan J, Kloecker G, Fleming C, Bousamra M, Hansen R, Hu X, Ding C, Cai Y, Xiang D, Donninger H, Eaton JW, Clark GJ. Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells. Oncoimmunology 2014; 3:e950163. [PMID: 25610737 DOI: 10.4161/15384101.2014.950163] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Accepted: 06/05/2014] [Indexed: 01/21/2023] Open
Abstract
Polymorphonuclear neutrophils (PMNs), the main effectors of the innate immune system, have rarely been considered as an anticancer therapeutic tool. However, recent investigations using animal models and preliminary clinical studies have highlighted the potential antitumor efficacy of PMNs. In the current study, we find that PMNs from some healthy donors naturally have potent cancer-killing activity against 4 different human cancer cell lines. The killing activity appears to be cancer cell-specific since PMNs did not kill primary normal epithelial cells or an immortalized breast epithelial cell line. Transfecting the immortalized mammary cells with plasmids expressing activated forms of the rat sarcoma viral oncogene homolog (Ras) and teratocarcinoma oncogene 21 (TC21) oncogenes was sufficient to provoke aggressive attack by PMNs. However, transfection with activated Ras-related C3 botulinum toxin substrate (Rac1) was ineffective, suggesting specificity in PMN-targeting of neoplastic cells. Furthermore, PMNs from lung cancer patients were also found to exhibit relatively poor cancer-killing activity compared to the cytolytic activity of the average healthy donor. Taken together, our results suggest that PMN-based treatment regimens may represent a paradigm shift in cancer immunotherapy that may be easily introduced into the clinic to benefit a subset of patients with PMN-vulnerable tumors.
Collapse
Key Words
- BEN, benign ethnic neutropenia
- DBL, proto-oncogene DBL
- DPI, diphenyleneiodonium
- E:T, effector:target
- G-CSF, granulocyte-colony stimulating factor
- GM-CSF, granulocyte macrophage-colony stimulating factor
- GVHD, graft-versus-host disease
- H-Ras, Harvey rat sarcoma viral oncogene homolog
- MEK, mitogen-activated protein kinase kinase
- NADPH, nicotinamide adenine dinucleotide phosphate
- NBT, nitroblue tetrazolium
- NSCLC, non-small cell lung carcinoma
- PI3 kinase, phosphoinositide 3-kinase
- PMN, polymorphonuclear neutrophils
- ROS, reactive oxygen species
- Rac1, Ras-related C3 botulinum toxin substrate 1
- RhoA, Ras homolog family member A
- TC-21, teratocarcinoma oncogene TC21
- TGFβ, transforming growth factor
- cytotoxicity
- mAb, monoclonal antibody
- mTOR, mammalian target of rapamycin
- neutrophils
- oncogene
- tumor cells
Collapse
Affiliation(s)
- Jun Yan
- Tumor Immunobiology Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA ; Division of Hematology/Oncology; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA
| | - Goetz Kloecker
- Division of Hematology/Oncology; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA
| | - Chris Fleming
- Tumor Immunobiology Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA
| | - Michael Bousamra
- Department of Cardiovascular Thoracic Surgery; University of Louisville ; Louisville, KY USA
| | - Richard Hansen
- Tumor Immunobiology Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA
| | - Xiaoling Hu
- Tumor Immunobiology Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA
| | - Chuanlin Ding
- Tumor Immunobiology Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA
| | - Yihua Cai
- Tumor Immunobiology Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA
| | - Dong Xiang
- Division of Hematology/Oncology; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA
| | - Howard Donninger
- Division of Hematology/Oncology; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA ; Molecular Targets Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA
| | - John W Eaton
- Division of Hematology/Oncology; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA ; Molecular Targets Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA
| | - Geoffrey J Clark
- Division of Hematology/Oncology; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA ; Molecular Targets Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA ; Department of Pharmacology and Toxicology; University of Louisville ; Louisville, KY USA
| |
Collapse
|
22
|
Holderness Parker N, Donninger H, Birrer MJ, Leaner VD. p21-activated kinase 3 (PAK3) is an AP-1 regulated gene contributing to actin organisation and migration of transformed fibroblasts. PLoS One 2013; 8:e66892. [PMID: 23818969 PMCID: PMC3688571 DOI: 10.1371/journal.pone.0066892] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2013] [Accepted: 05/12/2013] [Indexed: 01/01/2023] Open
Abstract
Activating Protein 1 (AP-1) plays a vital role in cell proliferation, differentiation and apoptosis. While de-regulation of AP-1 has been linked to many cancers, little is known regarding its downstream transcriptional targets that associate with cellular transformation. Previous studies identified PAK3, a serine/threonine kinase, as a potential AP-1 target gene. PAK3 has been implicated in a variety of pathological disorders and over-expression of other PAK-family members has been linked to cancer. In this study, we investigate AP-1 regulation of PAK3 expression and the role of PAK3 in cJun/AP-1-associated cellular transformation. Our results showed elevated PAK3 expression at both the mRNA and protein level in cJun-over-expressing Rat1a fibroblasts, as well as in transformed human fibroblasts. Elevated PAK3 expression in cJun/AP-1 over-expressing cells associated with a significant increase in PAK3 promoter activation. This increased promoter activity was lost when a single putative Jun binding site, which can bind AP-1 directly both in vitro and in vivo, was mutated. Further, inhibition of PAK3 using siRNA showed a regression in the cell morphology, migratory potential and actin organisation associated with AP-1 transformed cells. Our study is a first to describe a role for AP-1 in regulating PAK3 expression and suggest that PAK3 is an AP-1 target required for actin organization and migration observed in transformed cells.
Collapse
Affiliation(s)
- Nina Holderness Parker
- Division of Medical Biochemistry, Faculty of Health Sciences, University of Cape Town, Institute of Infectious Disease and Molecular Medicine, Cape Town, South Africa
| | - Howard Donninger
- Department of Medicine, James Graham Brown Cancer Center, Molecular Targets Program, University of Louisville, Louisville, Kentucky, United States of America
| | - Michael J. Birrer
- Harvard Medical School, Gynecologic Cancer Research Program, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
| | - Virna D. Leaner
- Division of Medical Biochemistry, Faculty of Health Sciences, University of Cape Town, Institute of Infectious Disease and Molecular Medicine, Cape Town, South Africa
- * E-mail:
| |
Collapse
|
23
|
Donninger H, Barnoud T, Nelson N, Kassler S, Clark J, Cummins TD, Powell DW, Nyante S, Millikan RC, Clark GJ. RASSF1A and the rs2073498 Cancer Associated SNP. Front Oncol 2011; 1:54. [PMID: 22649770 PMCID: PMC3355887 DOI: 10.3389/fonc.2011.00054] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2011] [Accepted: 12/06/2011] [Indexed: 12/23/2022] Open
Abstract
RASSF1A is one of the most frequently inactivated tumor suppressors yet identified in human cancer. It is pro-apoptotic and appears to function as a scaffolding protein that interacts with a variety of other tumor suppressors to modulate their function. It can also complex with the Ras oncoprotein and may serve to integrate pro-growth and pro-death signaling pathways. A SNP has been identified that is present in approximately 29% of European populations [rs2073498, A(133)S]. Several studies have now presented evidence that this SNP is associated with an enhanced risk of developing breast cancer. We have used a proteomics based approach to identify multiple differences in the pattern of protein/protein interactions mediated by the wild type compared to the SNP variant protein. We have also identified a significant difference in biological activity between wild type and SNP variant protein. However, we have found only a very modest association of the SNP with breast cancer predisposition.
Collapse
Affiliation(s)
- Howard Donninger
- Molecular Targets Program, Department of Medicine, James Graham Brown Cancer Center, University of Louisville Louisville, KY, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Donninger H, Allen N, Henson A, Pogue J, Williams A, Gordon L, Kassler S, Dunwell T, Latif F, Clark GJ. Salvador protein is a tumor suppressor effector of RASSF1A with hippo pathway-independent functions. J Biol Chem 2011; 286:18483-91. [PMID: 21489991 DOI: 10.1074/jbc.m110.214874] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
The RASSF1A tumor suppressor binds and activates proapoptotic MST kinases. The Salvador adaptor protein couples MST kinases to the LATS kinases to form the hippo pathway. Upon activation by RASSF1A, LATS1 phosphorylates the transcriptional regulator YAP, which binds to p73 and activates its proapoptotic effects. However, although serving as an adaptor for MST and LATS, Salvador can also bind RASSF1A. The functional role of the RASSF1A/Salvador interaction is unclear. Although Salvador is a novel tumor suppressor in Drosophila and mice, its role in human systems remains largely unknown. Here we show that Salvador promotes apoptosis in human cells and that Salvador inactivation deregulates the cell cycle and enhances the transformed phenotype. Moreover, we show that although the salvador gene is seldom mutated or epigenetically inactivated in human cancers, it is frequently down-regulated posttranscriptionally. Surprisingly, we also find that although RASSF1A requires the presence of Salvador for full apoptotic activity and to activate p73, this effect does not require a direct interaction of RASSF1A with MST kinases or the activation of the hippo pathway. Thus, we confirm a role for Salvador as a human tumor suppressor and RASSF1A effector and show that Salvador allows RASSF1A to modulate p73 independently of the hippo pathway.
Collapse
Affiliation(s)
- Howard Donninger
- Department of Medicine, JG Brown Cancer Center, Molecular Targets Program, CTR Building, University of Louisville, Louisville, Kentucky 40202, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Holderness N, Donninger H, Birrer MJ, Leaner V. The role of p21-activated kinase 3 (PAK3) in activating protein 1 (AP-1) induced oncogenesis. Clin Cancer Res 2010. [DOI: 10.1158/diag-10-a36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Activating protein 1 (AP-1) is a fundamental transcription factor that plays a role in cell proliferation, differentiation and apoptosis. Little is known about the role of the diverse downstream targets of the active AP-1 complex, a dimer comprising of the Jun, Fos or ATF bZIP-domain proteins. Deregulation of AP-1 has been linked to many cancers, with its over-expression leading to the transformation of normal cells. Previous studies utilizing a doxycycline-inducible cJun/AP-1 construct identified PAK3, a serine/threonine kinase signal transduction molecule, as a potential AP-1-target involved in the AP-1 characteristic transformation. PAK3 has been implicated in a variety of pathological disorders and over-expression of other PAK-family members has been linked to certain cancers. This project aims to investigate the role of PAK3 in cJun/AP-1 induced oncogenesis. Quantitative RT-PCR and Western Blot Analysis showed elevated PAK3 expression at both the mRNA and protein level in cJun-overexpressing cells. PAK3 expression levels were also elevated in transformed human and cancer cell lines compared to normal cells. Analysis of the PAK3 promoter using promoter luciferase assays identified a putative AP-1 binding site, at position +52 to +60, which may be responsible for the increased PAK3 promoter activity in response to cJun/AP-1 over-expression. siRNA inhibition of the PAK3 protein showed the regression of the morphological phenotype and migratory potential associated with cJun-transformed cells. However PAK3 inhibition showed no significant effect on the proliferative response of cJun-transformed cells. This study suggests a potential regulation of cJun/AP-1 on PAK3 as well as a role for PAK3 in AP-1 induced transformation; specifically that associated with cell morphology and migration.
Collapse
Affiliation(s)
| | | | | | - Virna Leaner
- 1University of Cape Town, Cape Town, South Africa
| |
Collapse
|
26
|
Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 2009; 16:521-32. [PMID: 19962670 PMCID: PMC3008560 DOI: 10.1016/j.ccr.2009.10.018] [Citation(s) in RCA: 195] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2007] [Revised: 12/02/2008] [Accepted: 10/22/2009] [Indexed: 11/19/2022]
Abstract
Advanced stage papillary serous tumors of the ovary are responsible for the majority of ovarian cancer deaths, yet the molecular determinants modulating patient survival are poorly characterized. Here, we identify and validate a prognostic gene expression signature correlating with survival in a series of microdissected serous ovarian tumors. Independent evaluation confirmed the association of a prognostic gene microfibril-associated glycoprotein 2 (MAGP2) with poor prognosis, whereas in vitro mechanistic analyses demonstrated its ability to prolong tumor cell survival and stimulate endothelial cell motility and survival via the alpha(V)beta(3) integrin receptor. Increased MAGP2 expression correlated with microvessel density suggesting a proangiogenic role in vivo. Thus, MAGP2 may serve as a survival-associated target.
Collapse
Affiliation(s)
- Samuel C. Mok
- Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Tomas Bonome
- Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA
| | - Vinod Vathipadiekal
- Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA
| | - Aaron Bell
- Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA
| | - Michael E. Johnson
- Department of Obstetrics, Gynecology and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - kwong-kwok Wong
- Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Dong-Choon Park
- Department of Obstetrics, Gynecology and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
- Department of Obstetrics and Gynecology, Saint Vincent Hospital, The Catholic University of Korea, Suwon, Gyeonggi-do 442-723, Korea
| | - Ke Hao
- Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA
| | - Daniel K.P. Yip
- Department of Physiology and Biophysics, University of South Florida, Tampa, FL 33612, USA
| | - Howard Donninger
- Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA
| | - Laurent Ozbun
- Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA
| | - Goli Samimi
- Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA
- Cancer Prevention Fellowship Program, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA
| | - John Brady
- Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA
| | - Mike Randonovich
- Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA
| | - Cindy A. Pise-Masison
- Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA
| | - J. Carl Barrett
- Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA
| | - Wing H. Wong
- Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA
| | - William R. Welch
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Ross S. Berkowitz
- Department of Obstetrics, Gynecology and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
- Gillette Center For Women’s Cancer, Dana-Farber Harvard Cancer Center, Boston, MA 02115, USA
| | - Michael J. Birrer
- Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA
- Correspondence:
| |
Collapse
|
27
|
Abstract
NORE1A (RASSF5) is a proapoptotic Ras effector that is frequently inactivated by promoter methylation in human tumors. It is structurally related to the RASSF1A tumor suppressor and is itself implicated as a tumor suppressor. In the presence of activated Ras, NORE1A is a potent inducer of apoptosis. However, when expressed at lower levels in the absence of activated Ras, NORE1A seems to promote cell cycle arrest rather than apoptosis. The mechanisms underlying NORE1A action are poorly understood. We have used microarray analysis of an inducible NORE1A system to screen for physiologic signaling targets of NORE1A action. Using this approach, we have identified several potential signaling pathways modulated by NORE1A. In particular, we identify the cyclin-dependent kinase inhibitor p21(CIP1) as a target for NORE1A activation and show that it is a vital component of NORE1A-mediated growth inhibition. In primary human hepatocellular carcinomas (HCC), loss of NORE1A expression is frequent and correlates tightly with loss of p21(CIP1) expression. NORE1A down-regulation in HCC also correlates with poor prognosis, enhanced proliferation, survival, and angiogenic tumor characteristics. Experimental inactivation of NORE1A results in the loss of p21(CIP1) expression and promotes proliferation. The best characterized activator of p21(CIP1) is the p53 master tumor suppressor. Further experiments showed that NORE1A activates p21(CIP1) via promoting p53 nuclear localization. Thus, we define the molecular basis of NORE1A-mediated growth inhibition and implicate NORE1A as a potential component of the ill-defined connection between Ras and p53.
Collapse
Affiliation(s)
- Diego F Calvisi
- Institut für Pathologie, Ernst-Moritz-Arndt-Universität, Greifswald, Germany
| | | | | | | | | | | | | |
Collapse
|
28
|
Leaner VD, Chick JF, Donninger H, Linniola I, Mendoza A, Khanna C, Birrer MJ. Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma. Am J Pathol 2008; 174:265-75. [PMID: 19074613 DOI: 10.2353/ajpath.2009.071006] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
A well-characterized murine osteosarcoma model for metastasis and invasion was used in this study to determine the role of AP-1 in the progression of this disease. We analyzed K12 and K7M2 cells, two clonally related murine osteosarcoma cell lines that have been characterized as low metastatic or high metastatic, respectively, for AP-1 components and activity. AP-1 DNA binding was similar between the two cell lines; however AP-1 transcriptional activity was enhanced by 3- to 5-fold in K7M2 cells relative to that in K12 cells. The AP-1 complexes in K12 and K7M2 cells was composed primarily of cJun, JunD, FosB, Fra1, and Fra2, with the contribution of individual components in the complex varying between the two cell lines. In addition, an increase in phosphorylated cJun, JNK activity, and phosphorylated ERK1/2 was associated with the more metastatic osteosarcoma phenotype. The significance of AP-1 activation was confirmed by conditional expression of TAM67, a dominant negative mutant of cJun. Under conditions where TAM67 inhibited AP-1 activity in K7M2 cells, migration and invasion potential was significantly blocked. Tam67 expression in aggressive osteosarcoma cells decreased long-term in vivo experimental metastasis and increased survival of mice. This study shows that differences in metastatic activity can be due to AP-1 activation. The inhibition of AP-1 activity may serve as a therapeutic tool in the management of osteosarcoma.
Collapse
Affiliation(s)
- Virna D Leaner
- Cell and Cancer Biology Department, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
The p53 tumour suppressor gene is frequently mutated in human tumours and different tumour-derived mutations have varying effects on cells. The effect of a novel tumour-derived p53 mutation and two recently described mutations from South African breast cancer patients on the growth rate, colony formation, cell cycle arrest after irradiation and response to chemotherapeutic drugs was investigated. None of the p53 mutations had any significant effect on the inherent growth rate of the cells; however, contact inhibition of growth in two of the mutants was lost. These same two mutants formed colonies in soft agar, whereas the third mutant did not. All three of the mutants failed to show a G(1) cell cycle arrest after exposure to 7 Gy of [(60)Co] radiation, albeit to different degrees. Cells expressing the p53 mutants were either more sensitive to cisplatin and melphalan or more resistant than the untransfected cells, depending on the mutation. However, there was no difference in response to daunorubicin treatment. These results demonstrate that different p53 mutations exert varying biological effects on normal cells, with some altering checkpoint activation more effectively than others. The data also suggest that the nature of the p53 mutation influences the sensitivity to cytostatic drugs.
Collapse
Affiliation(s)
- Howard Donninger
- Division of Medical Biochemistry, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory 7925, South Africa
| | | | | | | |
Collapse
|
30
|
Matsha T, Donninger H, Erasmus RT, Hendricks D, Stepien A, Parker MI. Expression of p53 and its homolog, p73, in HPV DNA positive oesophageal squamous cell carcinomas. Virology 2007; 369:182-90. [PMID: 17761206 DOI: 10.1016/j.virol.2007.07.025] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2007] [Revised: 07/03/2007] [Accepted: 07/13/2007] [Indexed: 11/21/2022]
Abstract
Several studies have detected human papilloma virus (HPV) DNA in squamous cell carcinoma of the oesophagus (OSCC). In this study, we analysed OSCC specimens from 114 patients for the presence of HPV DNA, and p53 and p73 expression. HPV DNA was detected in 44.7% of cases, with the low risk HPV11 occurring most frequently. p53 and p73 expression was detected in 70% and 61.4% of cases, respectively. There was no correlation between expression of p53, p73 or HPV infection and tumour grade, or between p53 expression and the presence of HPV DNA. There was, however, significant correlation between p73 expression and the presence of HPV DNA (p<0.01) and p53 and p73 co-expression (p<0.001), as well as co-expression of p53 and p73 with HPV status (p<0.05). These data support previous studies suggesting a role for HPV infection in OSCC and also indicate that HPV infection and p53 and p73 overexpression are not mutually exclusive. In addition, the data implicate a role for p73 in OSCC and suggest a complex interaction between p53, p73 and HPV in the aetiology of the disease.
Collapse
Affiliation(s)
- T Matsha
- Division of Medical Biochemistry, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, 7925, South Africa
| | | | | | | | | | | |
Collapse
|
31
|
Abstract
RASSF1A (Ras association domain family 1 isoform A) is a recently discovered tumor suppressor whose inactivation is implicated in the development of many human cancers. Although it can be inactivated by gene deletion or point mutations, the most common contributor to loss or reduction of RASSF1A function is transcriptional silencing of the gene by inappropriate promoter methylation. This epigenetic mechanism can inactivate numerous tumor suppressors and is now recognized as a major contributor to the development of cancer. RASSF1A lacks apparent enzymatic activity but contains a Ras association (RA) domain and is potentially an effector of the Ras oncoprotein. RASSF1A modulates multiple apoptotic and cell cycle checkpoint pathways. Current evidence supports the hypothesis that it serves as a scaffold for the assembly of multiple tumor suppressor complexes and may relay pro-apoptotic signaling by K-Ras.
Collapse
Affiliation(s)
- Howard Donninger
- Molecular Targets Group, Department of Medicine, J. G. Brown Cancer Center, University of Louisville, 119C Baxter Boulevard, 580 S. Preston Street, Louisville, KY 40202, USA
| | | | | |
Collapse
|
32
|
Allen NPC, Donninger H, Vos MD, Eckfeld K, Hesson L, Gordon L, Birrer MJ, Latif F, Clark GJ. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 2007; 26:6203-11. [PMID: 17404571 DOI: 10.1038/sj.onc.1210440] [Citation(s) in RCA: 105] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
RASSF family proteins are tumor suppressors that are frequently downregulated during the development of human cancer. The best-characterized member of the family is RASSF1A, which is downregulated by promoter methylation in 40-90% of primary human tumors. We now identify and characterize a novel member of the RASSF family, RASSF6. Like the other family members, RASSF6 possesses a Ras Association domain and binds activated Ras. Exogenous expression of RASSF6 promoted apoptosis, synergized with activated K-Ras to induce cell death and inhibited the survival of specific tumor cell lines. Suppression of RASSF6 enhanced the tumorigenic phenotype of a human lung tumor cell line. Furthermore, RASSF6 is often downregulated in primary human tumors. RASSF6 shares some similar overall properties as other RASSF proteins. However, there are significant differences in biological activity between RASSF6 and other family members including a discrete tissue expression profile, cell killing specificity and impact on signaling pathways. Moreover, RASSF6 may play a role in dictating the degree of inflammatory response to the respiratory syncytial virus. Thus, RASSF6 is a novel RASSF family member that demonstrates the properties of a Ras effector and tumor suppressor but exhibits biological properties that are unique and distinct from those of other family members.
Collapse
Affiliation(s)
- N P C Allen
- Department of Cell and Cancer Biology, National Cancer Institute, Rockville, MD, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
|
34
|
Wu K, Liu M, Li A, Donninger H, Rao M, Jiao X, Lisanti MP, Cvekl A, Birrer M, Pestell RG. Cell fate determination factor DACH1 inhibits c-Jun-induced contact-independent growth. Mol Biol Cell 2006; 18:755-67. [PMID: 17182846 PMCID: PMC1805093 DOI: 10.1091/mbc.e06-09-0793] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The cell fate determination factor DACH1 plays a key role in cellular differentiation in metazoans. DACH1 is engaged in multiple context-dependent complexes that activate or repress transcription. DACH1 can be recruited to DNA via the Six1/Eya bipartite transcription (DNA binding/coactivator) complex. c-Jun is a critical component of the activator protein (AP)-1 transcription factor complex and can promote contact-independent growth. Herein, DACH1 inhibited c-Jun-induced DNA synthesis and cellular proliferation. Excision of c-Jun with Cre recombinase, in c-jun(f1/f1) 3T3 cells, abrogated DACH1-mediated inhibition of DNA synthesis. c-Jun expression rescued DACH1-mediated inhibition of cellular proliferation. DACH1 inhibited induction of c-Jun by physiological stimuli and repressed c-jun target genes (cyclin A, beta-PAK, and stathmin). DACH1 bound c-Jun and inhibited AP-1 transcriptional activity. c-jun and c-fos were transcriptionally repressed by DACH1, requiring the conserved N-terminal (dac and ski/sno [DS]) domain. c-fos transcriptional repression by DACH1 requires the SRF site of the c-fos promoter. DACH1 inhibited c-Jun transactivation through the delta domain of c-Jun. DACH1 coprecipitated the histone deacetylase proteins (HDAC1, HDAC2, and NCoR), providing a mechanism by which DACH1 represses c-Jun activity through the conserved delta domain. An oncogenic v-Jun deleted of the delta domain was resistant to DACH1 repression. Collectively, these studies demonstrate a novel mechanism by which DACH1 blocks c-Jun-mediated contact-independent growth through repressing the c-Jun delta domain.
Collapse
Affiliation(s)
- Kongming Wu
- *Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107
| | - Manran Liu
- *Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107
| | - Anping Li
- *Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107
| | - Howard Donninger
- Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
| | - Mahadev Rao
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057; and
| | - Xuanmao Jiao
- *Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107
| | - Michael P. Lisanti
- *Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107
| | - Ales Cvekl
- Departments of Ophthalmology and Visual Sciences and Molecular Genetics, Albert Einstein College of Medicine, New York, NY 10461
| | - Michael Birrer
- Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
| | - Richard G. Pestell
- *Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107
| |
Collapse
|
35
|
Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, Mok SC, Brady J, Bonome T, Birrer MJ. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 2006; 66:8404-12. [PMID: 16951150 DOI: 10.1158/0008-5472.can-06-0683] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Ovarian cancer is resistant to the antiproliferative effects of transforming growth factor-beta (TGF-beta); however, the mechanism of this resistance remains unclear. We used oligonucleotide arrays to profile 37 undissected, 68 microdissected advanced-stage, and 14 microdissected early-stage papillary serous cancers to identify signaling pathways involved in ovarian cancer. A total of seven genes involved in TGF-beta signaling were identified that had altered expression >1.5-fold (P < 0.001) in the ovarian cancer specimens compared with normal ovarian surface epithelium. The expression of these genes was coordinately altered: genes that inhibit TGF-beta signaling (DACH1, BMP7, and EVI1) were up-regulated in advanced-stage ovarian cancers and, conversely, genes that enhance TGF-beta signaling (PCAF, TFE3, TGFBRII, and SMAD4) were down-regulated compared with the normal samples. The microarray data for DACH1 and EVI1 were validated using quantitative real-time PCR on 22 microdissected ovarian cancer specimens. The EVI1 gene locus was amplified in 43% of the tumors, and there was a significant correlation (P = 0.029) between gene copy number and EVI1 gene expression. No amplification at the DACH1 locus was found in any of the samples. DACH1 and EVI1 inhibited TGF-beta signaling in immortalized normal ovarian epithelial cells, and a dominant-negative DACH1, DACH1-Delta DS, partially restored signaling in an ovarian cancer cell line resistant to TGF-beta. These results suggest that altered expression of these genes is responsible for disrupted TGF-beta signaling in ovarian cancer and they may be useful as new and novel therapeutic targets for ovarian cancer.
Collapse
Affiliation(s)
- Jan S Sunde
- Walter Reed Army Medical Center, Washington, District of Columbia, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Vos MD, Dallol A, Eckfeld K, Allen NPC, Donninger H, Hesson LB, Calvisi D, Latif F, Clark GJ. The RASSF1A Tumor Suppressor Activates Bax via MOAP-1. J Biol Chem 2006; 281:4557-63. [PMID: 16344548 DOI: 10.1074/jbc.m512128200] [Citation(s) in RCA: 112] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The novel tumor suppressor RASSF1A is frequently inactivated during human tumorigenesis by promoter methylation. RASSF1A may serve as a node in the integration of signaling pathways controlling a range of critical cellular functions including cell cycle, genomic instability, and apoptosis. The mechanism of action of RASSF1A remains under investigation. We now identify a novel pathway connecting RASSF1A to Bax via the Bax binding protein MOAP-1. RASSF1A and MOAP-1 interact directly, and this interaction is enhanced by the presence of activated K-Ras. RASSF1A can activate Bax via MOAP-1. Moreover, activated K-Ras, RASSF1A, and MOAP-1 synergize to induce Bax activation and cell death. Analysis of a tumor-derived point mutant of RASSF1A showed that the mutant was defective for the MOAP-1 interaction and for Bax activation. Moreover, inhibition of RASSF1A by shRNA impaired the ability of K-Ras to activate Bax. Thus, we identify a novel pro-apoptotic pathway linking K-Ras, RASSF1A and Bax that is specifically impaired in some human tumors.
Collapse
Affiliation(s)
- Michele D Vos
- Department of Cell and Cancer Biology, NCI, National Institutes of Health, Rockville, Maryland 20850-3300, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Kling S, Donninger H, Williams Z, Vermeulen J, Weinberg E, Latiff K, Ghildyal R, Bardin P. Persistence of rhinovirus RNA after asthma exacerbation in children. Clin Exp Allergy 2005; 35:672-8. [PMID: 15898992 DOI: 10.1111/j.1365-2222.2005.02244.x] [Citation(s) in RCA: 96] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Rhinoviruses (RVs) are believed to cause most asthma exacerbations but their role in the severity of acute asthma and subsequent recovery of airway function is not defined. The importance of atopy in virus-host interactions is also not clear. OBJECTIVE We postulated that RV infection and atopic skin prick responses influence the severity of asthma exacerbations as measured by peak expiratory flow (PEF). METHODS Patients aged 4-12 years admitted with acute severe asthma to a hospital emergency room (ER) were recruited. PEF measurements were obtained and nasal aspirates (NA) were taken. Atopy was diagnosed by skin prick responses to allergen and the presence of RV RNA and respiratory syncytial virus (RSV) RNA in NAs was detected using validated PCR assays. Patients were restudied after 6 weeks and after 6 months. RESULTS Fifty children with acute asthma (mean age+/-SD, 7.4+/-2.7) were enrolled; atopy was present in 37 (74%). RV RNA was detected in 41 (82%) and RSV RNA in six (12%) subjects. After 6 weeks 41 patients were restudied and RV RNA was again detected in 18 (44%). RV RNA was detected after 6 months in four of 16 patients restudied (25%; P=0.008 vs. ER) and in two of nine children from a control group with stable asthma (22%; P=0.009 vs. ER). Overall PEF measurements were reduced in asthmatics admitted to ER (% predicted, 63.4+/-16.4%) but did not differ between patients with RV RNA, RSV RNA or neither virus present. In subjects with RV RNA detectable in ER and after 6 weeks, measurements of PEF in ER were significantly lower than in patients in whom RV RNA was present in ER but absent after 6 weeks (P=0.009). Regression analysis linked persistence of RV RNA, but not skin prick responses to allergen, to severity of PEF reductions in ER. CONCLUSION RV RNA was detectable in >40% of asthmatic children 6 weeks after an acute exacerbation. Asthma exacerbations were more severe in patients with persistence of RV RNA suggesting that the severity of acute asthma may be linked to prolonged and possibly more severe RV infections.
Collapse
Affiliation(s)
- S Kling
- Department of Paediatrics and Lung Unit, University of Stellenbosch, Cape Town, South Africa
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Bonome T, Park DC, Hao K, Donninger H, Radonovich M, Brady J, Barrett JC, Wong WH, Welch WR, Mok SC, Birrer MJ. Identification of a gene signature that can predict lone-term survival in patients with high-grade late stage serous ovarian cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. Bonome
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA; Harvard Sch of Public Health, Boston, MA
| | - D.-C. Park
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA; Harvard Sch of Public Health, Boston, MA
| | - K. Hao
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA; Harvard Sch of Public Health, Boston, MA
| | - H. Donninger
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA; Harvard Sch of Public Health, Boston, MA
| | - M. Radonovich
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA; Harvard Sch of Public Health, Boston, MA
| | - J. Brady
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA; Harvard Sch of Public Health, Boston, MA
| | - J. C. Barrett
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA; Harvard Sch of Public Health, Boston, MA
| | - W. H. Wong
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA; Harvard Sch of Public Health, Boston, MA
| | - W. R. Welch
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA; Harvard Sch of Public Health, Boston, MA
| | - S. C. Mok
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA; Harvard Sch of Public Health, Boston, MA
| | - M. J. Birrer
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA; Harvard Sch of Public Health, Boston, MA
| |
Collapse
|
39
|
Donninger H, Bonome T, Li JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Barrett JC, Mok SC, Birrer MJ. Expression profiling of microdissected papillary serous ovarian epithelial cancers identifies genes describing the unique phenotypes of borderline and malignant tumors. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Donninger
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA
| | - T. Bonome
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA
| | - J.-Y. Li
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA
| | - D.-C. Park
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA
| | - M. Radonovich
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA
| | - C. Pise-Masison
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA
| | - J. Brady
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA
| | - J. C. Barrett
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA
| | - S. C. Mok
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA
| | - M. J. Birrer
- National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA
| |
Collapse
|
40
|
Leaner VD, Donninger H, Ellis CA, Clark GJ, Birrer MJ. p75-Ras-GRF1 is a c-Jun/AP-1 target protein: its up regulation results in increased Ras activity and is necessary for c-Jun-induced nonadherent growth of Rat1a cells. Mol Cell Biol 2005; 25:3324-37. [PMID: 15798216 PMCID: PMC1069594 DOI: 10.1128/mcb.25.8.3324-3337.2005] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
The c-Jun/AP-1 transcription complex is associated with diverse cellular processes such as differentiation, proliferation, transformation, and apoptosis. These different biological endpoints are likely achieved by the regulation of specific target gene expression. We describe the identification of Ras guanine nucleotide exchange factor 1, Ras-GRF1, by microarray analysis as a c-Jun/AP-1 regulated gene essential for anchorage-independent growth of immortalized rat fibroblasts. Increased Ras-GRF1 expression, in response to inducible c-Jun expression in Rat1a fibroblasts, was confirmed by both real-time PCR and Northern blot analysis. We show that c-Jun/AP-1 can bind and activate the Ras-GRF1 promoter in vivo. A 75-kDa c-Jun/AP-1-inducible protein, p75-Ras-GRF1, was detected, and the inhibition of its expression with antisense oligomers significantly blocked c-Jun-regulated anchorage-independent cell growth. p75-Ras-GRF1 expression occurred with a concomitant increase in activated Ras (GTP bound), and the activation of Ras was significantly inhibited by antisense Ras-GRF1 oligomers. Moreover, p75-Ras-GRF1 could be coprecipitated with a Ras dominant-negative glutathione S-transferase (GST) construct, GST-Ras15A, demonstrating an interaction between p75-Ras-GRF1 and Ras. A downstream target of Ras activation, Elk-1, had increased transcriptional activity in c-Jun-expressing cells, and this activation was inhibited by dominant-negative Ras. In addition, c-Jun overexpression resulted in an increase in phospho-AKT while phosphorylation of ERK1/2 remained largely unaffected. The inhibition of phosphatidylinositol 3-kinase (PI3K)-AKT signal transduction by Ly294002 and wortmannin significantly blocked c-Jun-regulated morphological transformation, while inhibition of basal MEK-ERK activity with PD98059 and U0126 had little effect. We conclude that c-Jun/AP-1 regulates endogenous p75-Ras-GRF1 expression and that c-Jun/AP-1-regulated anchorage-independent cell growth requires activation of Ras-PI3K-AKT signal transduction.
Collapse
Affiliation(s)
- Virna D Leaner
- National Cancer Institute, 9610 Medical Center Dr., Room 300, Rockville, MD 20850-3300, USA
| | | | | | | | | |
Collapse
|
41
|
Katabami M, Donninger H, Hommura F, Leaner VD, Kinoshita I, Chick JFB, Birrer MJ. Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorage-independent growth in RAT1a cells. J Biol Chem 2005; 280:16728-38. [PMID: 15737994 DOI: 10.1074/jbc.m413892200] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Overexpression of c-Jun enables Rat1a cells to grow in an anchorage-independent manner. We used an inducible c-Jun system under the regulation of doxycycline in Rat1a cells to identify potential c-Jun target genes necessary for c-Jun-induced anchorage-independent growth. Induction of c-Jun results in sustained expression of cyclin A in the nonadherent state with only minimal expression in the absence of c-Jun. The promoter activity of cyclin A2 was 4-fold higher in Rat1a cells in which c-Jun expression was induced compared with the control cells. Chromatin immunoprecipitation demonstrated that c-Jun bound directly to the cyclin A2 promoter. Mutation analysis of the cyclin A2 promoter mapped the c-Jun regulatory site to an ATF site at position -80. c-Jun was able to bind to this site both in vitro and in vivo, and mutation of this site completely abolished promoter activity. Cyclin A1 was also elevated in c-Jun-overexpressing Rat1a cells; however, c-Jun did not regulate this gene directly, since it did not bind directly to the cyclin A1 promoter. Suppression of cyclin A expression via the introduction of a cyclin A antisense sequences significantly reduced the ability of c-Jun-overexpressing Rat1a cells to grow in an anchorage-independent fashion. Taken together, these results suggest that cyclin A is a target of c-Jun and is necessary but not sufficient for c-Jun-induced anchorage-independent growth. In addition, we demonstrated that the cytoplasmic oncogenes Ras and Src transcriptionally activated the cyclin A2 promoter via the ATF site at position -80. Using a dominant negative c-Jun mutant, TAM67, we showed that this transcriptional activation of cyclin A2 requires c-Jun. Thus, our results suggest that c-Jun is a mediator of the aberrant cyclin A2 expression associated with Ras/Src-induced transformation.
Collapse
Affiliation(s)
- Motoo Katabami
- Department of Cell and Cancer Biology, NCI, National Institutes of Health, Rockville, Maryland 20850, USA
| | | | | | | | | | | | | |
Collapse
|
42
|
Ghildyal R, Dagher H, Donninger H, de Silva D, Li X, Freezer NJ, Wilson JW, Bardin PG. Rhinovirus infects primary human airway fibroblasts and induces a neutrophil chemokine and a permeability factor. J Med Virol 2005; 75:608-15. [PMID: 15714497 DOI: 10.1002/jmv.20315] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The events linking rhinovirus (RV) infection to airway symptoms are poorly understood. The virus initially infects airway epithelium followed by a vigorous inflammatory response that may entail spread of RV from epithelium to other cells in the airway wall. However, RV has fastidious growth characteristics and to date reproductive infection of primary cells other than human airway epithelium has not been confirmed. Airway fibroblasts are adjacent to and in contact with epithelial cells, play a key role in innate immune responses, and may participate in the evolution of inflammation. To investigate fibroblast actions, we first determined whether RV could infect and replicate in primary culture human lung fibroblasts. RV serotype 16 (RV16) was used to infect fibroblasts grown from lung tissue, and virus infection with replication was demonstrated by a combination of techniques. RT-PCR was used to show an increase in RV transcription; confocal microscopy demonstrated colocalization of the replicative form of RV genome (double-stranded RNA) and RV16 proteins; infectious virus was also recovered from the culture supernatant of infected fibroblasts. Functional consequences of RV infection were next examined. RV infection of fibroblasts was followed by an increase in epithelial neutrophil-activating peptide-78 (ENA-78) mRNA and protein. The permeability factor vascular endothelial growth factor (VEGF) was also induced over a similar time course. These data suggest that interactions between RV and human fibroblasts are feasible, may coordinate neutrophil chemoattraction with enhanced vascular permeability and that fibroblasts may contribute to inflammatory responses following RV infections.
Collapse
Affiliation(s)
- Reena Ghildyal
- Department of Respiratory Medicine, Medicine and Surgery, Monash Medical Centre and Monash Center for Inflammatory Diseases, Monash University, 246 Clayton Road, Clayton 3168, Melbourne, Australia
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, Barrett JC, Birrer MJ. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004; 23:8065-77. [PMID: 15361855 DOI: 10.1038/sj.onc.1207959] [Citation(s) in RCA: 103] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Ovarian cancer is the most lethal type of gynecologic cancer in the Western world. The high case fatality rate is due in part because most ovarian cancer patients present with advanced stage disease which is essentially incurable. In order to obtain a whole genome assessment of aberrant gene expression in advanced ovarian cancer, we used oligonucleotide microarrays comprising over 40,000 features to profile 37 advanced stage papillary serous primary carcinomas. We identified 1191 genes that were significantly (P < 0.001) differentially regulated between the ovarian cancer specimens and normal ovarian surface epithelium. The microarray data were validated using real time RT-PCR on 14 randomly selected differentially regulated genes. The list of differentially expressed genes includes ones that are involved in cell growth, differentiation, adhesion, apoptosis and migration. In addition, numerous genes whose function remains to be elucidated were also identified. The microarray data were imported into PathwayAssist software to identify signaling pathways involved in ovarian cancer tumorigenesis. Based on our expression results, a signaling pathway associated with tumor cell migration, spread and invasion was identified as being activated in advanced ovarian cancer. The data generated in this study represent a comprehensive list of genes aberrantly expressed in serous papillary ovarian adenocarcinoma and may be useful for the identification of potentially new and novel markers and therapeutic targets for ovarian cancer.
Collapse
Affiliation(s)
- Howard Donninger
- Department of Cell and Cancer Biology, National Cancer Institute, Rockville, MD 20850, USA
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Dagher H, Donninger H, Hutchinson P, Ghildyal R, Bardin P. Rhinovirus detection: comparison of real-time and conventional PCR. J Virol Methods 2004; 117:113-21. [PMID: 15041207 DOI: 10.1016/j.jviromet.2004.01.003] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2003] [Revised: 12/11/2003] [Accepted: 01/08/2004] [Indexed: 11/20/2022]
Abstract
Rhinoviruses are important human respiratory viruses and the major causative agents of the common cold. Historically, detection of rhinovirus has been by virus culture and this was significantly improved by the use of PCR assays. Recently real-time PCR was developed but to date there have been no reported comparisons of conventional and real-time PCR assays for detection of rhinovirus. In this study, we first compared real-time PCR (SYBR Green I) to conventional PCR for the detection of rhinovirus in serially diluted standard DNA and rhinovirus stock to determine the limits of detection. Next, assays were compared for sensitivity to detect rhinovirus in cell culture with a known number of infected cells. Finally, the assays were compared using clinical samples known to contain rhinovirus. Real-time PCR was 10-fold more sensitive than conventional PCR to detect rhinovirus in standard DNA and in virus stock and >10-fold more sensitive to detect rhinovirus in cultured cells. Real-time PCR was significantly superior for detection of rhinovirus in patients' nasal aspirates (sensitivity 72% versus 39%, P < 0.05). In summary, we found that real-time PCR was more sensitive than conventional PCR and reduced post-PCR processing. Hence, real-time PCR is suitable for both research and clinical purposes.
Collapse
Affiliation(s)
- Hayat Dagher
- Department of Respiratory Medicine, Monash Centre for Inflammatory Diseases, Monash Medical Centre and University, Melbourne, Australia.
| | | | | | | | | |
Collapse
|
45
|
Donninger H, Cashmore TJ, Scriba T, Petersen DC, Janse van Rensburg E, Hayes VM. Functional analysis of novel SLC11A1 (NRAMP1) promoter variants in susceptibility to HIV-1. J Med Genet 2004; 41:e49. [PMID: 15060125 PMCID: PMC1735753 DOI: 10.1136/jmg.2003.013318] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- H Donninger
- Department of Internal Medicine, University of Stellenbosch, Tygerberg, South Africa
| | | | | | | | | | | |
Collapse
|
46
|
Hommura F, Katabami M, Leaner VD, Donninger H, Sumter TF, Resar LM, Birrer MJ. HMG-I/Y Is a c-Jun/Activator Protein-1 Target Gene and Is Necessary for c-Jun–Induced Anchorage-Independent Growth in Rat1a Cells. Mol Cancer Res 2004. [DOI: 10.1158/1541-7786.305.2.5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The transcription complex activator protein-1 (AP-1) plays a role in a diverse number of cellular processes including proliferation, differentiation, and apoptosis. To identify AP-1–responsive target genes, we used a doxycycline-inducible c-Jun system in Rat1a cells. The HMG-I/Y chromatin binding protein was found to be up-regulated by c-Jun. Following induction of c-Jun expression, Rat1a cells under nonadherent growth conditions have sustained HMG-I/Y mRNA expression and 2-fold higher protein than uninduced cells. HMG-I/Y promoter reporter assays show that HMG-I/Y promoter activity increases in the presence of c-Jun expression, and gel mobility shift assays demonstrate that induced c-Jun binds to an AP-1 consensus site at position −1,091 in the HMG-I/Y promoter. Suppression of HMG-I/Y expression by its antisense sequence significantly reduces the ability of c-Jun–overexpressing Rat1a cells to grow in an anchorage-independent fashion. HMG-I/Y transforms Rat1a cells (although the colonies are smaller than that observed for the cells overexpressing c-Jun). Taken together, these results suggest that HMG-I/Y is a direct transcriptional target of c-Jun necessary for c-Jun–induced anchorage-independent growth in Rat1a cells.
Collapse
Affiliation(s)
- Fumihiro Hommura
- 1Cell and Cancer Biology Branch, National Cancer Institute, Rockville, Maryland and
| | - Motoo Katabami
- 1Cell and Cancer Biology Branch, National Cancer Institute, Rockville, Maryland and
| | - Virna D. Leaner
- 1Cell and Cancer Biology Branch, National Cancer Institute, Rockville, Maryland and
| | - Howard Donninger
- 1Cell and Cancer Biology Branch, National Cancer Institute, Rockville, Maryland and
| | - Takita F. Sumter
- 2Departments of Pediatrics and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Linda M.S. Resar
- 2Departments of Pediatrics and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Michael J. Birrer
- 1Cell and Cancer Biology Branch, National Cancer Institute, Rockville, Maryland and
| |
Collapse
|
47
|
Hommura F, Katabami M, Leaner VD, Donninger H, Sumter TF, Resar LMS, Birrer MJ. HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells. Mol Cancer Res 2004; 2:305-14. [PMID: 15192124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The transcription complex activator protein-1 (AP-1) plays a role in a diverse number of cellular processes including proliferation, differentiation, and apoptosis. To identify AP-1-responsive target genes, we used a doxycycline-inducible c-Jun system in Rat1a cells. The HMG-I/Y chromatin binding protein was found to be up-regulated by c-Jun. Following induction of c-Jun expression, Rat1a cells under nonadherent growth conditions have sustained HMG-I/Y mRNA expression and 2-fold higher protein than uninduced cells. HMG-I/Y promoter reporter assays show that HMG-I/Y promoter activity increases in the presence of c-Jun expression, and gel mobility shift assays demonstrate that induced c-Jun binds to an AP-1 consensus site at position -1,091 in the HMG-I/Y promoter. Suppression of HMG-I/Y expression by its antisense sequence significantly reduces the ability of c-Jun-overexpressing Rat1a cells to grow in an anchorage-independent fashion. HMG-I/Y transforms Rat1a cells (although the colonies are smaller than that observed for the cells overexpressing c-Jun). Taken together, these results suggest that HMG-I/Y is a direct transcriptional target of c-Jun necessary for c-Jun-induced anchorage-independent growth in Rat1a cells.
Collapse
Affiliation(s)
- Fumihiro Hommura
- Cell and Cancer Biology Branch, National Cancer Institute, Rockville, MD, USA
| | | | | | | | | | | | | |
Collapse
|
48
|
Donninger H, Glashoff R, Haitchi HM, Syce JA, Ghildyal R, van Rensburg E, Bardin PG. Rhinovirus induction of the CXC chemokine epithelial-neutrophil activating peptide-78 in bronchial epithelium. J Infect Dis 2003; 187:1809-17. [PMID: 12751040 DOI: 10.1086/375246] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2002] [Accepted: 01/06/2003] [Indexed: 11/03/2022] Open
Abstract
Epithelial-neutrophil activating peptide-78 (ENA-78) induces neutrophil migration, an early response to viral infection. Rhinovirus serotype 16 (RV16) was used to infect primary bronchial epithelial cells and a cell line (BEAS-2B). Release of ENA-78 protein was measured by enzyme-linked immunosorbent assay, ENA-78 mRNA production was quantified by reverse-transcription polymerase chain reaction, and ENA-78 promoter activity was assessed by use of a promoter construct. After infection with RV16, ENA-78 protein and mRNA increased significantly, and RV16 induced 3-fold increases in ENA-78 gene transcription. Nasal ENA-78 measured in patients with asthma with and without RV infection was more elevated in patients with RV infection present. Our study demonstrates that ENA-78 is produced in bronchial epithelial cells in response to RV16 infection. With other chemokines, it may be an important initiator of neutrophil airway inflammation during RV common colds and thus may play a role in the development of virus-associated airway pathologies.
Collapse
Affiliation(s)
- Howard Donninger
- Lung and Allergy Unit and Medical Virology, University of Stellenbosch, Cape Town, South Africa
| | | | | | | | | | | | | |
Collapse
|
49
|
|
50
|
Abstract
PURPOSE To examine the role of p53 mutations in the modulation of DNA repair and radiotoxicity by pentoxifylline. MATERIALS AND METHODS NIH3T3 murine cells transfected with mutant p53 constructs were examined for the influence of pentoxifylline on radiotoxicity to Co(60) gamma-irradiation by colony assay. DNA repair (0-100 Gy) was measured by constant-field gel electrophoresis. Apoptosis was assessed by flow cytometry with the annexin-V-binding assay. RESULTS In the two p53 hot-spot mutant cell lines p53-S269R and p53- + 15, the SF(10) radiotoxicity enhancement factors induced by the pentoxifylline were 8.0 and 9.7, respectively. In the p53 deletion mutant p53-DeltaA cell line, the radiotoxicity enhancement factor was 2.6. No radiosensitization was obtained in the untransfected p53 wild-type cell line U-Wt and in the transfected p53 double-wild-type p53-Wt cell line. When pentoxifylline was added after irradiation at the time of maximum G2 block expression, no radiosensitization was observed in any of the five cell lines. Constant-field gel electrophoresis analyses after 20 h of repair showed that pentoxifylline suppresses DNA double-strand break repair in all p53 mutant cell lines, as indicated by repair inhibition factors of 2.0-2.3. No repair suppression was found in the p53 wild-type cell lines. CONCLUSIONS p53 mutations are a general requirement for radiosensitization by pentoxifylline and the level of radiosensitization depends upon the location of the p53 mutation.
Collapse
Affiliation(s)
- A Binder
- Department of Radiation Oncology, Radiobiology Laboratory, University of Stellenbosch, Faculty of Health and Tygerberg Hospital, PO Box 19063, Tygerberg 7505, South Africa.
| | | | | | | | | |
Collapse
|